Peptides have shifted from clinical use into consumer-facing wellness products, driven by telehealth access and celebrity endorsement. The FDA’s decision to revisit restrictions on certain unapproved peptides places that trend under renewed scrutiny. For brands, the core issue is not access alone, but how marketing, product positioning, and liability exposure intersect as the agency reopens the door.
The Rise of Peptide-Based Products in Telehealth and Influencer Channels
Peptides now sit at the center of a fast-growing category that blends medical treatment with consumer branding. Telehealth platforms prescribe compounded peptide formulations for weight loss, recovery, and longevity, often delivered through subscription models.
Celebrity and influencer promotion has accelerated adoption. Public figures frame these therapies as performance tools, while platforms emphasize convenience and personalization, creating a hybrid between prescription care and lifestyle product.
That positioning creates immediate legal tension. A product marketed with therapeutic intent but distributed through consumer-style channels invites scrutiny under both FDA drug standards and FTC advertising rules.
FDA Advisory Committee Review of Unapproved Peptides Signals Potential Reversal of 2023 Restrictions
The FDA’s Pharmacy Compounding Advisory Committee is scheduled to meet in mid-2026 to evaluate whether several previously restricted peptides should be allowed back into compounding. This follows the agency’s 2023 decision to place a group of peptides into a high-risk category, effectively blocking their use by compounding pharmacies. The upcoming review will focus on whether certain peptides can be added to the 503A Bulks List, which governs what substances may be compounded pursuant to a prescription. That determination will shape whether these products can re-enter regulated medical channels.
The review reflects a shift in how the FDA is approaching the issue. In 2023, the agency cited limited clinical data, potential immune reactions, and manufacturing concerns as the basis for restricting these substances. Now, the committee will reassess whether those risks outweigh the consequences of limiting access, particularly as demand has continued through telehealth platforms and alternative supply chains. Industry pressure and broader policy considerations have contributed to this reassessment.
For brands, the outcome introduces a narrow and uncertain pathway. A peptide may become legally compoundable without being FDA-approved, leaving open questions around safety, efficacy, and permissible marketing claims. That distinction creates exposure where products can be sold under medical supervision but still challenged under advertising or product liability theories. The committee’s conclusions will not resolve those tensions, but they will define the boundaries within which companies operate.
FDA Advisory Committee Review and the 503A Bulks List Implications
The FDA’s planned advisory committee review introduces a possible reversal. The agency will evaluate whether certain peptides should be added to the 503A Bulks List, which determines which substances compounding pharmacies may legally use.
Inclusion on that list does not equate to approval. It permits compounding under physician prescription, but leaves questions of safety, efficacy, and marketing substantiation unresolved.
For brands, the distinction is operational. A peptide may become legally compoundable while remaining vulnerable to enforcement if claims exceed available evidence. The reopening of this pathway changes supply options but does not resolve liability exposure.
Influencer Marketing Claims and FTC Enforcement Risk in Peptide Products
Influencer and celebrity endorsements have become central to peptide product growth. These endorsements often rely on personal experience narratives tied to weight loss, recovery, or anti-aging outcomes.
The FTC requires that such claims be truthful, substantiated, and clearly disclosed. In the peptide category, that requirement is difficult to satisfy where clinical evidence is limited or inconsistent.
A brand that amplifies influencer claims assumes responsibility for those statements. If the underlying data does not support the advertised benefits, enforcement risk extends beyond the endorser to the company itself.
Product Liability Exposure for Compounded Peptides and Wellness Brands
Compounded peptides occupy a narrow legal space. They are not FDA-approved drugs, yet they are used in medical contexts and marketed to consumers with therapeutic implications.
This creates a dual exposure profile. Plaintiffs may challenge products based on alleged misrepresentation, while also raising product liability claims tied to safety or adverse effects.
The most exposed products are those positioned as outcome-driven. Weight loss injections, recovery therapies, and longevity treatments invite scrutiny where expectations are high and evidence is limited. The closer a product moves toward drug-like claims, the more likely it is to attract litigation.
The Legal Gap: Compounding Legality Does Not Confer Marketing Protection
Mainstream coverage has focused on whether the FDA will allow peptides back into compounding. The more consequential issue is what that allowance does not provide.
Compounding legality does not shield a brand from false advertising claims. It does not establish that a product is safe or effective, and it does not validate marketing narratives built around performance outcomes.
This gap creates a false sense of security. Companies may interpret FDA flexibility as a signal to expand offerings or claims, when the enforcement risk may increase as visibility grows.
The Juris Law Group Perspective on FDA and Advertising Risk for CPG and Wellness Brands
Emerging health categories blur the line between regulated medical products and consumer goods. As CPG attorneys, we navigate enforcement challenges where product claims, labeling, and distribution models intersect.
In the peptide category, that intersection is acute. Brands must manage how products are described across websites, telehealth platforms, and influencer channels, while maintaining substantiation that can withstand scrutiny.
Our FDA and advertising attorneys work alongside trademark protection lawyers to align product positioning with defensible claims. That includes reviewing marketing language, evaluating substantiation standards, and structuring product launches to mitigate enforcement exposure.
Strategic Outlook: FDA Peptide Policy and Brand Risk Over the Next 12 Months
The FDA’s advisory committee review will likely result in a partial reopening of compounding pathways for certain peptides. That shift will expand access through regulated channels, particularly for telehealth-driven platforms.
At the same time, increased availability will attract closer scrutiny. Enforcement activity may shift from supply restrictions to marketing practices, with regulators and plaintiffs focusing on how products are positioned rather than whether they can be compounded.
Brands entering or re-entering the peptide space should expect a more visible and contested market. The next phase will test whether companies can align demand-driven marketing with defensible legal positions.
Common Legal Inquiries
Can a peptide be legally sold if it is added to the 503A Bulks List?
Yes, but only through compounding under a valid prescription. That status does not equate to FDA approval, and it does not eliminate exposure under advertising or product liability laws if claims are not properly substantiated.
Are influencer claims about peptide products enforceable against brands?
Yes. If a brand compensates or directs an influencer, it may be held responsible for the claims made. Those claims must be supported by reliable evidence and comply with FTC disclosure and substantiation requirements.
Does FDA compounding allowance reduce litigation risk?
No. It changes the supply pathway but does not protect against claims related to misleading marketing, safety concerns, or consumer expectations. Brands must evaluate risk across both regulatory and litigation frameworks.
